(Q35536165)

8 August 2017

title

Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections (English)

1 reference

8 August 2017

Fass RJ

1

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 February 1987

1 reference

Antimicrobial Agents and Chemotherapy

8 August 2017

published in

1 reference

8 August 2017

volume

31

1 reference

8 August 2017

issue

2

1 reference

8 August 2017

page(s)

148-150

1 reference

Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Quantitative definition of bacteriuria

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

In vitro activity of ciprofloxacin (Bay o 9867)

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Norfioxacin (MK–0366) treatment of urinary tract infections in hospitalized patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

A Critical Evaluation of Nalidixic Acid in Urinary-Tract Infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Clinical experience with ciprofloxacin in the USA.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=174680

Clinical evaluation of treatment with ciprofloxacin

26 September 2018

1 reference

12 December 2020

Is the clean-catch midstream void procedure necessary for obtaining urine culture specimens from men?

1 reference

12 December 2020

1 reference

12 December 2020

Enoxacin treatment of urinary tract infections

1 reference

12 December 2020

Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection

1 reference

12 December 2020

Diagnosis of coliform infection in acutely dysuric women

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.31.2.148

1 reference

8 August 2017

1 reference

8 August 2017

1 reference